WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317953
CAS#: 63585-09-1 (sodium)
Description: Foscarnet is a structural mimic of the anion pyrophosphate that selectively inhibits the pyrophosphate binding site on viral DNA polymerases at concentrations that do not affect human DNA polymerases. In individuals treated with the DNA polymerase inhibitors acyclovir or ganciclovir, HSV or CMV particles can develop mutant protein kinases (thymidine kinase or UL97 protein kinase, respectively) that make them resistant to these antiviral drugs. However, unlike acyclovir and ganciclovir, foscarnet is not activated by viral protein kinases, making it useful in acyclovir- or ganciclovir-resistant HSV and CMV infections.
Hodoodo Cat#: H317953
Name: Foscarnet Sodium
CAS#: 63585-09-1 (sodium)
Chemical Formula: CNa3O5P
Exact Mass: 0.00
Molecular Weight: 191.950
Elemental Analysis: C, 6.26; Na, 35.93; O, 41.68; P, 16.14
Related CAS #: 63585-09-1 (sodium) 4428-95-9 (free acid)
Synonym: Foscarnet Sodium;
IUPAC/Chemical Name: trisodium;phosphonatoformate
InChi Key: DFHAXXVZCFXGOQ-UHFFFAOYSA-K
InChi Code: InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3
SMILES Code: C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
Appearance: Solid powder
Purity: >97% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 191.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Irie K, Hiramoto N, Yamaoka K, Fuckushima S. Cerebrospinal fluid concentration of foscarnet in patients with HHV-6 encephalitis after haematopoietic stem cell transplantation. J Antimicrob Chemother. 2023 Apr 18:dkad117. doi: 10.1093/jac/dkad117. Epub ahead of print. PMID: 37071595.
2: Vittayawacharin P, E'Leimat G, Lee BJ, Griffin S, Doh J, Nam H, Blodget E, Jeyakumar D, Kongtim P, Ciurea SO. Once-Daily Foscarnet Is Effective for Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 Mar 4:S2666-6367(23)01132-6. doi: 10.1016/j.jtct.2023.02.022. Epub ahead of print. PMID: 36878429.
3: Ma R, He Y, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ, Sun YQ. [Clinical analysis of the efficacies of ganciclovir plus foscarnet and a single antiviral drug for the treatment of cytomegalovirus infection after haploidentical stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2023 Jan 1;62(1):76-83. Chinese. doi: 10.3760/cma.j.cn112138-20220118-00058. PMID: 36631041.
4: Garikapati S, Nguyen M. Foscarnet. 2023 Jan 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32310568.
5: Lee HJ, Woo SJ. Efficacy of ganciclovir versus foscarnet in ganciclovir- resistant cytomegalovirus retinitis: A case report. Eur J Ophthalmol. 2022 Oct 30:11206721221136316. doi: 10.1177/11206721221136316. Epub ahead of print. PMID: 36314436.
6: Cho J, Bhavsar AR, Cho DH, Sattarova V, Abel AS, Zadroga R. Successful Treatment of Epstein-Barr Virus-Induced Necrotizing Retinitis with Intravitreous Ganciclovir, Foscarnet, and Methotrexate. Case Rep Ophthalmol. 2022 Mar 4;13(1):116-123. doi: 10.1159/000520408. PMID: 35431884; PMCID: PMC8958626.
7: Khorenko M, Rand U, Cicin-Sain L, Feldmann C. Foscarnet-Type Inorganic- Organic Hybrid Nanoparticles for Effective Antiviral Therapy. ACS Biomater Sci Eng. 2022 Apr 11;8(4):1596-1603. doi: 10.1021/acsbiomaterials.2c00074. Epub 2022 Mar 28. PMID: 35344659; PMCID: PMC9007112.
8: Suzuki K, Namba K, Hase K, Mizuuchi K, Iwata D, Ito T, Kitaichi N, Takase H, Ishida S. A case of Epstein-Barr virus acute retinal necrosis successfully treated with foscarnet. Am J Ophthalmol Case Rep. 2022 Jan 29;25:101363. doi: 10.1016/j.ajoc.2022.101363. PMID: 35146210; PMCID: PMC8818534.
9: Inose R, Takahashi K, Takahashi M, Sugimoto T, Nanno S, Hino M, Nagayama K. Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study. Transpl Infect Dis. 2022 Apr;24(2):e13804. doi: 10.1111/tid.13804. Epub 2022 Feb 10. PMID: 35114030.
10: Hermoso-Fernández FM, Gonzalez-Gallardo C, Cruz-Rojo M. Acute retinal necrosis: time to consider double dose of Foscarnet in the first 72 hours. Rom J Ophthalmol. 2021 Jul-Sep;65(3):267-270. doi: 10.22336/rjo.2021.53. PMID: 35036649; PMCID: PMC8697778.
11: Irie K, Hiramoto N, Ishikawa T, Fukushima S. Use of liquid chromatography- tandem mass spectrometry for foscarnet quantification in human serum and cerebrospinal fluid. Rapid Commun Mass Spectrom. 2022 Apr 15;36(7):e9255. doi: 10.1002/rcm.9255. PMID: 35001441.
12: Pleško J, Kovač D, Arsov Z, Lindič J, Škoberne A, Ferluga D, Kojc N. Glomerular and tubulointerstitial foscarnet nephropathy of kidney allograft with emphasis on ultrastructural findings: A case report. Clin Nephrol. 2021 Suppl;96(1):127-132. doi: 10.5414/CNP96S23. PMID: 34643504.
13: Yu Y, Bao R, Lyu J, Wu J, Chen J, Peng W. Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration. Infect Drug Resist. 2021 Jul 27;14:2911-2923. doi: 10.2147/IDR.S321936. PMID: 34349526; PMCID: PMC8326942.
14: Rho E, Näf B, Müller TF, Wüthrich RP, Schachter T, von Moos S. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. Clin Transplant. 2021 Nov;35(11):e14401. doi: 10.1111/ctr.14401. Epub 2021 Oct 28. PMID: 34181768; PMCID: PMC9285377.
15: Ota R, Hirata A. Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet. J Chemother. 2021 Dec;33(8):539-546. doi: 10.1080/1120009X.2021.1915074. Epub 2021 Jun 1. PMID: 34060436.
16: Domingo W, Nguyen IT, Johnsrud JJ, Brown JW. Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients. Transplant Cell Ther. 2021 Jul;27(7):622.e1-622.e5. doi: 10.1016/j.jtct.2021.03.018. Epub 2021 Mar 23. PMID: 33891883.
17: Zarrouk K, Zhu X, Pham VD, Goyette N, Piret J, Shi R, Boivin G. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0039021. doi: 10.1128/AAC.00390-21. Epub 2021 Jun 17. PMID: 33875432; PMCID: PMC8218610.
18: Miyao K, Terakura S, Ozawa Y, Sawa M, Kohno A, Kasahara S, Iida H, Ino K, Kusumoto S, Kasai M, Takami A, Kurahashi S, Kajiguchi T, Morishita T, Nishida T, Murata M; Nagoya Blood and Marrow Transplantation Group. Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. Transplant Cell Ther. 2021 Apr;27(4):342.e1-342.e10. doi: 10.1016/j.jtct.2020.12.012. Epub 2020 Dec 16. PMID: 33836887.
19: Vassallo F, Nuzzi R, Cattani I, Dellacasa C, Giaccone L, De Rosa FG, Cavallo R, Iovino G, Brunello L, Bruno B, Busca A. CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins. Ther Adv Hematol. 2020 Dec 10;11:2040620720975651. doi: 10.1177/2040620720975651. PMID: 33354311; PMCID: PMC7734499.
20: Deffert C, Stoermann C, Ernandez T, Nabergoj M, Chalandon Y, Jaeger P. Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury. Kidney Int Rep. 2020 Aug 22;5(11):2102-2108. doi: 10.1016/j.ekir.2020.08.019. PMID: 33163731; PMCID: PMC7609899.
